Early Briefing and Review: Gilead Sciences, InterMune, NPS Pharma, and Halozyme Therapeutics PR Newswire LONDON, August 6, 2013 LONDON, August 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Monday, August 5, 2013, the S&P 500 closed 0.15% lower at 1,707.14. Shares in biotechnology companies ended on a mixed note as the broader market edged lower. The major movers in the sector included Gilead Sciences Inc. (NASDAQ: GILD), InterMune Inc. (NASDAQ: ITMN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and Halozyme Therapeutics Inc. (NASDAQ: HALO). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at: http://www.aaaresearchreports.com/register/ Shares in Gilead Sciences Inc. fell sharply on Monday as the broader market declined. The company's shares ended the day 1.30% lower at $60.95 after fluctuating between $60.43 and $61.90. A total of 6.11 million shares were traded, which is below the daily average volume of 11.01 million. Gilead Sciences' shares have declined 0.73% in the last three trading sessions. Nevertheless, Gilead Sciences' stock is trading above its 50-day and 200-day moving averages. Sign up for free report on GILD at: http://www.AAAResearchReports.com/GILD080613.pdf InterMune Inc.'s stock closed slightly lower on Monday as the broader market ended on a declining note. The company's shares fluctuated between $15.49 and $15.90 before finishing the day 0.89% lower at $15.52. A total of 1.10 million shares were traded, which is below the daily average volume of 1.43 million. Despite Monday's pullback, InterMune's shares have gained 0.06% in the last three trading sessions. ITMN free technical report can be accessed by signing up at: http://www.AAAResearchReports.com/ITMN080613.pdf Shares in NPS Pharmaceuticals Inc. edged higher on Monday, extending their gains from previous trading sessions. The company's shares oscillated between $18.55 and $19.06 before finishing the day 0.96% higher at $18.92. A total of 1.23 million shares were traded, which is below the daily average volume of 1.56 million. NPS Pharmaceuticals' shares have gained 42.79% in the last three months, outperforming the S&P 500 which has gained 5.74% during the same period. Furthermore, the stock is currently trading near its 52-week high of $19.06. A free report on NPSP can be accessed by registering at: http://www.AAAResearchReports.com/NPSP080613.pdf Halozyme Therapeutics Inc.'s stock rose sharply on Monday. The company's shares closed the day 2.70% higher at $7.24. A total of 1.79 million shares were traded, which is above the daily average volume of 1.52 million. The stock is trading below its 50-day moving average. In the last three months, Halozyme Therapeutics' shares have advanced 19.87%, outperforming the S&P 500 which has gained 5.74% during the same period. Register with AAA Research Reports and download research on HALO for free at: http://www.AAAResearchReports.com/HALO080613.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. http://www.AAAresearchreports.com SOURCE AAA Research Reports Contact: Media Contact: Phone #: +1-(646)-396-9126
Early Briefing and Review: Gilead Sciences, InterMune, NPS Pharma, and Halozyme Therapeutics
Press spacebar to pause and continue. Press esc to stop.